Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to Strong Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded Compass Therapeutics from “sell” to “strong sell,” contrasting with the broader analyst consensus of “Moderate Buy” and an average price target of $11.77.
• CMPX shares opened at $2.15, near their 52-week low, while the company reported a quarterly loss of $0.13 per share—$0.02 worse than analysts expected.
• Institutional investors own 68.43% of Compass Therapeutics, with several hedge funds recently initiating or increasing positions in the clinical-stage immuno-oncology company.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued on Saturday.

Several other equities analysts have also recently issued reports on the company. D. Boral Capital restated a "buy" rating and set a $30.00 price objective on shares of Compass Therapeutics in a research note on Monday, April 27th. Canaccord Genuity Group lowered their target price on shares of Compass Therapeutics from $13.00 to $7.00 and set a "buy" rating for the company in a research note on Tuesday, April 28th. LADENBURG THALM/SH SH started coverage on shares of Compass Therapeutics in a report on Wednesday, July 1st. They set a "buy" rating and a $5.00 target price on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Compass Therapeutics in a report on Friday, July 17th. Finally, Stifel Nicolaus set a $6.00 price target on shares of Compass Therapeutics in a research report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Compass Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $11.77.

Compass Therapeutics Stock Up 8.0%

Shares of NASDAQ CMPX opened at $2.15 on Friday. The stock's 50 day moving average price is $2.09 and its two-hundred day moving average price is $3.86. Compass Therapeutics has a 52-week low of $1.61 and a 52-week high of $6.88. The stock has a market capitalization of $387.19 million, a P/E ratio of -5.37 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, analysts anticipate that Compass Therapeutics will post -0.42 EPS for the current year.

Institutional Trading of Compass Therapeutics

Several hedge funds have recently made changes to their positions in CMPX. Russell Investments Group Ltd. grew its stake in Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock worth $27,000 after buying an additional 7,592 shares during the last quarter. Parallel Advisors LLC bought a new stake in Compass Therapeutics in the first quarter valued at $28,000. Creative Planning acquired a new position in shares of Compass Therapeutics during the second quarter valued at $30,000. State of Wyoming bought a new position in shares of Compass Therapeutics during the second quarter worth about $31,000. Finally, Flagship Harbor Advisors LLC acquired a new stake in shares of Compass Therapeutics in the 4th quarter worth about $32,000. Institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source